Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
1997-06-27
2001-08-28
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C424S460000, C514S002600, C514S012200, C530S300000, C530S350000, C530S324000, C435S069100
Reexamination Certificate
active
06280739
ABSTRACT:
FIELD OF THE INVENTION
The present invention provides novel proteins, along with therapeutic, diagnostic and research utilities for these proteins.
BACKGROUND OF THE INVENTION
Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides “directly” in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent “indirect” cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins that the present invention is directed.
SUMMARY OF THE INVENTION
In one embodiment, the present invention provides a composition comprising an isolated protein encoded by a polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 14 to nucleotide 400;
(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AM931 deposited under accession number ATCC 98026;
(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AM931 deposited under accession number ATCC 98026;
(e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AM931 deposited under accession number ATCC 98026;
(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AM931 deposited under accession number ATCC 98026;
(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity;
(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; and
(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 14 to nucleotide 400; the nucleotide sequence of the full-length protein coding sequence of clone AM931 deposited under accession number ATCC 98026; or the nucleotide sequence of the mature protein coding sequence of clone AM931 deposited under accession number ATCC 98026. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone AM931 deposited under accession number ATCC 98026. In yet other preferred embodiments, such polynucleotide encodes a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120. In further preferred embodiments, such polynucleotide encodes a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acid 86 to amino acid 128.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:2;
(b) the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120;
(c) the amino acid sequence of SEQ ID NO:2 from amino acid 86 to amino acid 128;
(d) fragments of the amino acid sequence of SEQ ID NO:2; and
(e) the amino acid sequence encoded by the cDNA insert of clone
AM931 deposited under accession number ATCC 98026; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2, or the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120, or the amino acid sequence of SEQ ID NO:2 from amino acid 86 to amino acid 128.
Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.
Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier. Preferably such methods comprise treating a subject to produce an effect selected from the group consisting of inhibition of angiogenesis, inhibition of growth or proliferation of vascular endothelial cells, inhibition of tumor growth and inhibition of angiogenesis-dependent tissue growth.
REFERENCES:
patent: 3920853 (1975-11-01), Middendorf et al.
patent: 5227158 (1993-07-01), Jardieu
patent: 5338839 (1994-08-01), McKay et al.
patent: 5405749 (1995-04-01), Polans et al.
patent: 5472866 (1995-12-01), Gerald et al.
patent: 5536637 (1996-07-01), Jacobs
patent: WO 94/01548 (1994-01-01), None
patent: WO 95/34573 (1995-12-01), None
patent: WO 96/00738 (1996-01-01), None
patent: WO 97/39122 (1997-10-01), None
Snider et al. EMBL/GenBank/DDBJ Data Bank, Accession No. 088317, 1998.*
Theoharides GenBank Database, Accession No. W27693, 1998.*
Ayala, F.J. et al., “Modern Genetics,” 2d Ed. Benjamine/Cummings: Menlo Park, CA, p. G1 (1984).
Bishop, D.H.L. et al.Membrane Protein Expression Systems. London: Portland Press. 1994, pp. 83-124.
Callard et al., “The cytokine factsbook,” Academic Press, Harcourt Brace and Company: London, UK, pp. 39-40 (1994).
Cheung et al. “Gene expression of adult human heart as revealed by random sequencing of cDNA library”Protein Engineering9:90 (1995).
Ganong et al., “Review of Medical Physiology,” Appleton & Lange: Norwalk, CT pp. 219, 220, 446 (1995).
GenBank Accession No. R78830 for yi90c06.r1 Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE: 146506 5′, mRNA sequence; No date, author.
GenBank Accession No. D32249 forRattus norvegicusmRNA for neurodegeneration associated protein 1, complete cds No date, author.
GenBank Accession No. H45398 for yn99g10.r1 Soares adult brain N2b5HB55Y Homo sapiens cDNA clone IMAGE:176610 5′, mRNA sequence No date, author.
GenBank Accession No. AA016124 for ze31b06.r1 Soares retina N2b4HR Homo sapiens cDNA clone IMAGE:360563 5′, mRNA sequence.
GenBank Accession No. AA041196 for zf09e05.s1 Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone IMAGE:376448 3′, mRNA sequence.
GenBank Accession No. AA054467 for zk82b02.r1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:489291 5′, mRNA sequence.
GenBank Accession No. Q61260 for.
GenBank Accession No. R18560 for yf95b10.r1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:30142 5′, mRNA sequence.
GenBank Accession No. R41427 for yf95b10.s1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:30142 3′, mRNA sequence.
GenBank Accession No. T96696 for ye51a01.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:121224 5′, mRNA sequence.
GenBank Accession No. H42872 for yo68a05.s1 Soares breast 3NbHBst Homo sapiens cDNA clone IMAGE:183056 3′, mRNA sequence.
GenBank Accession No. H42936 for yo68a05.r1 Soares breast 3NbHBst Homo sapiens cDNA clone IMAGE:183056 5′, mRNA sequence.
GenBank Accession No. N92574 for zb27a10.s1 Soares_parathyroid_tumor_NbHPA Homo sapiens cDNA clone IMAGE:304794 3′, mRNA sequence.
GenBank Accession No. R81889 for yj03b05.r1 Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE:147633 5′, mRNA sequence.
GenBan
Evans Cheryl
Jacobs Kenneth
LaVallie Edward R.
McCoy John M.
Merberg David
Carlson Karen Cochrane
Genetics Institute Inc.
Houze Thomas A.
Lahive & Cockfield LLP
Lauro Peter C.
LandOfFree
Method of inhibiting angiogenesis using secreted proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting angiogenesis using secreted proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting angiogenesis using secreted proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2509368